Abstract
ABCC6 promotes the efflux of ATP from hepatocytes to the bloodstream. ATP is then cleaved to AMP and pyrophosphate, a major inhibitor of ectopic calcification. Pathogenic variants of ABCC6 cause pseudoxanthoma elasticum, a recessive ectopic calcification disease of highly variable severity. One of the mechanisms influencing the heterogeneity of a disorder is the penetrance of pathogenic variants. Penetrance shows the proportion of carriers developing the phenotype; hence incomplete penetrance indicates that the disease does not necessarily develop in the presence of specific variants. Here, we investigated whether incomplete penetrance contributes to the heterogeneity of pseudoxanthoma elasticum. By integrating the clinical and genetic data of 589 patients, we created the largest European cohort. Based on allele frequencies compared to a reference cohort, we identified two incomplete penetrant variants, p.V787I and p.R391G, 6.5% and 2% penetrance, respectively. The characterization of the p.R391G variant suggested unaltered severity of the clinical phenotype. Based on our biochemical and localization studies, we hypothesize that the variant becomes deleterious only if an interacting partner is mutated simultaneously. Our data reveal the potential existence of the first interacting partner of ABCC6. Our data are also important for genetic counseling, as they suggest lower disease heritability of some variants.
Competing Interest Statement
Authors gratefully acknowledge the collaboration of people affected by PXE and the support of PXE International and other patient associations. This work is a result of a collaboration in the frame of the EuroSoftCalcNet COST Action (CA16-115). This work was supported by the National Research Development and Innovation Office [NKFIH, FK131946], U.S Department of State [Fulbright Visiting Scholar Program], Hungarian Academy of Sciences [Bolyai Janos Fellowship BO/00730/19/8] and by the UNKP-2021 New National Excellence Program of the Ministry for Innovation and Technology from the source of the NKFIH to FS. Further funding for this work was provided by PXE International and the NIH NIAMS Grant R01AR072695 (KvdW), PXE Italia Odv (DQ). SV is a PhD Fellow supported by a Methusalem grant from the Ghent University - Belgium (BOF08/01M01108). OMV is a Senior Clinical Investigator of the Research Foundation Flanders (FWO) - Belgium. MTA-SE Lendulet Research Grant (LP2015-11/2015) of the Hungarian Academy of Sciences the KH125566, K135798 grants to KT and the Ministry of Human Capacities in Hungary in the frame of Institutional Excellence Program for Higher Education. Diagnosis and management of PXE DNA samples occurred at the PXE Reference Center (MAGEC Nord), Angers University Hospital, Angers, France, as a part of the French PXE cohort (ClinicalTrials.gov Identifier: NCT01446380). TA is a beneficiary of the NKFIH K132695 grant.
Funding Statement
This work is a result of a collaboration in the frame of the EuroSoftCalcNet COST Action (CA16-115). This work was supported by the National Research, Development and Innovation Office [NKFIH, FK131946], U.S Department of State [Fulbright Visiting Scholar Program], Hungarian Academy of Sciences [Bolyai Janos Fellowship BO/00730/19/8, Mobility grant] and by the UNKP-2020 New National Excellence Program of the Ministry for Innovation and Technology from the source of the NKFIH to FS. Further funding for this work was provided by PXE International and the National Institutes of Health Grant R01AR072695 (KvdW). SV is a PhD Fellow supported by a Methusalem grant from the Ghent University - Belgium (BOF08/01M01108). OMV is a Senior Clinical Investigator of the Research Foundation Flanders (FWO) - Belgium. MTA-SE Lendulet Research Grant (LP2015-11/2015) of the Hungarian Academy of Sciences, the KH125566, K135798 grants to KT and the Ministry of Human Capacities in Hungary in the frame of Institutional Excellence Program for Higher Education. Diagnosis and management of PXE DNA samples occurred at the PXE Reference Center (MAGEC Nord), Angers University Hospital, Angers, France, as a part of the French PXE cohort (ClinicalTrials.gov Identifier: NCT01446380). TA is a beneficiary of the NKFIH K132695 grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
PXE patients signed an informed consent. The study was approved by the University Hospital of Angers, the Ethics Committee of the University of Ghent, and the local Ethics Committee for the University of Modena and Reggio Emilia and the Declaration of Helsinki was followed. The US patients were recruited under the IRB of Thomas Jefferson University, PA and the Genetic Alliance IRB protocol PXE #001.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data obtained are included in the manuscript.